TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from DaVita ( (DVA) ).
On November 24, 2025, DaVita Inc. amended its Credit Agreement to establish new secured term loan and revolving credit facilities totaling up to $3.5 billion. This financial restructuring aims to refinance existing debt and support general corporate purposes, potentially enhancing DaVita’s financial flexibility and operational capabilities.
The most recent analyst rating on (DVA) stock is a Hold with a $143.00 price target. To see the full list of analyst forecasts on DaVita stock, see the DVA Stock Forecast page.
Spark’s Take on DVA Stock
According to Spark, TipRanks’ AI Analyst, DVA is a Neutral.
DaVita’s overall stock score is primarily influenced by its financial performance and valuation. While the company shows strong cash flow and is undervalued, it faces significant challenges in profitability and financial stability. The technical analysis indicates bearish momentum, adding to the cautious outlook.
To see Spark’s full report on DVA stock, click here.
More about DaVita
DaVita Inc. operates in the healthcare industry, primarily providing kidney care services, including dialysis treatment. It focuses on improving the quality of life for patients with chronic kidney disease and end-stage renal disease.
Average Trading Volume: 894,037
Technical Sentiment Signal: Hold
Current Market Cap: $8.44B
See more insights into DVA stock on TipRanks’ Stock Analysis page.